Abstract:Lanthanide-doped upconversion nanoparticles (UCNPs) have the ability to generate ultraviolet or visible emissions under continuous-wave near-infrared (NIR) excitation. Utilizing this special luminescence property, UCNPs are approved as a new generation of contrast agents in optical imaging with deep tissue-penetration ability and high signal-to-noise ratio. The integration of UCNPs with other functional moieties can endow them with highly enriched functionalities for imaging-guided cancer therapy, which makes … Show more
“…24,25 NO-hybrid composites that combine NO to existing drugs such as photosensitizing agents used in photodynamic therapy might afford an advantage of combining the effects of NO with the benefits of drugs to overcome tumor cell resistance to conventional therapeutic agents. 17,18,26,27 Photothermal therapy (PTT), which is based on the principle of converting light energy into heat to generate hyperthermia, is another promising effective treatment for tumor necrosis because of its high selectivity and noninvasiveness.…”
Nitric oxide (NO) plays important roles in various physiological and pathological processes. The development of multifunctional nanoplatforms that enable site-specific delivery of NO is expected to provide new insights toward the realization of NO-mediated therapy. We report herein a novel nanoplatform {Lyso-Ru-NO@FA@CDs}, (1), where a lysosome-targeting NO donor, Lyso-Ru-NO, and a folic-acid (FA)-directing group were incorporated into carbon dots (CDs).Nanoplatform 1 exhibited immediate NO release and a rapid temperature increase when irradiated with an 808-nm laser.This nanoplatform was capable of targeting folate-receptor-positive cancer cell lines and specifically accumulated in the subcellular lysosomal organelle. The duel-targeted nanoplatform 1 exhibited high cytotoxicity toward cancer cells under irradiation with 808-nm light, demonstrating substantially enhanced efficacy compared with its nontargeted counterparts.NIR-light-controlled spatiotemporal delivery of NO to targeted sites accompanied by photothermal therapy offers new possibilities for NO-involved multimodal cancer treatment.
“…24,25 NO-hybrid composites that combine NO to existing drugs such as photosensitizing agents used in photodynamic therapy might afford an advantage of combining the effects of NO with the benefits of drugs to overcome tumor cell resistance to conventional therapeutic agents. 17,18,26,27 Photothermal therapy (PTT), which is based on the principle of converting light energy into heat to generate hyperthermia, is another promising effective treatment for tumor necrosis because of its high selectivity and noninvasiveness.…”
Nitric oxide (NO) plays important roles in various physiological and pathological processes. The development of multifunctional nanoplatforms that enable site-specific delivery of NO is expected to provide new insights toward the realization of NO-mediated therapy. We report herein a novel nanoplatform {Lyso-Ru-NO@FA@CDs}, (1), where a lysosome-targeting NO donor, Lyso-Ru-NO, and a folic-acid (FA)-directing group were incorporated into carbon dots (CDs).Nanoplatform 1 exhibited immediate NO release and a rapid temperature increase when irradiated with an 808-nm laser.This nanoplatform was capable of targeting folate-receptor-positive cancer cell lines and specifically accumulated in the subcellular lysosomal organelle. The duel-targeted nanoplatform 1 exhibited high cytotoxicity toward cancer cells under irradiation with 808-nm light, demonstrating substantially enhanced efficacy compared with its nontargeted counterparts.NIR-light-controlled spatiotemporal delivery of NO to targeted sites accompanied by photothermal therapy offers new possibilities for NO-involved multimodal cancer treatment.
“…[4][5][6][7][8][9] When functionalized with appropriate surface moieties gold nanoparticles can enter living cells, which makes them attractive candidates for their use as therapeutic agents. [10] One promising surface modification is DNA.…”
In this paper we present chemical methods developed in our laboratory to synthesize nanoparticles for biomedical and imaging applications. We show that branched gold nanoparticles can be used for imaging applications whereas gold nanorods can be successfully coated with materials such as silica making them ideal for further bio-functionalization.
“…[7][8][9][10] In general, the main investigations on lanthanide-based upconversion nanoparticle activators are confined to a few rare-earth ions (Er 3+ , Tm 3+ and Ho 3+ ) with proper intermediary energy states to match the sensitizer Yb 3+ . [11][12][13] Few articles exist on achieving efficient upconversion emission from other rare-earth ions such as Tb 3+ and Eu 3+ .…”
Upconversion luminescence nanomaterials have shown great potential in biological and physical applications because of their unique properties. However, limited research exists on the cooperative sensitization upconversion emission in Tb(3+) ions over Er(3+) ions and Tm(3+) ions because of its low efficiency. Herein, by optimizing the doping ratio of sensitizer and activator to maximize the utilization of the photon energy and introducing the CaF2 inert shell to shield sensitizer from quenchers, we synthesize ultrasmall NaYbF4:Tb@CaF2 nanoparticles with a significant enhancement (690-fold) in cooperative sensitization upconversion emission intensity, compared with the parent NaYbF4:Tb. The lifetime of Tb(3+) emission in NaYbF4:Tb@CaF2 nanoparticles is prolonged extensively to ∼3.5 ms. Furthermore, NaYbF4:Tb@CaF2 was applied in in vitro and in vivo bioimaging. The presented luminescence enhancement strategy provides cooperative sensitization upconversion with new opportunities for bioapplication.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.